Trial comparisons

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=11

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04505722-e20eadc8",
        "title": "Double-blind Phase: Ad26.COV2.S 5*10^10 vp vs Double-blind Phase: Placebo: Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 Regardless of Their Serostatus (Double Blind Phase)",
        "summary": "575 of 21898 against 1189 of 21890; risk difference -2.8 points, 95% interval -3.2 to -2.4; NCT04505722, A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants",
        "record": "/library/comparisons/NCT04505722-e20eadc8",
        "nct_id": "NCT04505722",
        "kind": "outcome",
        "participants": 43788,
        "risk_difference": {
          "value": -0.028058933981092035,
          "lower": -0.031752284483248655,
          "upper": -0.024397532615813157
        },
        "group_1": "575 of 21,898",
        "group_2": "1,189 of 21,890",
        "difference": "-2.8 points",
        "interval": "-3.2 to -2.4",
        "trial_title": "A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants"
      },
      {
        "id": "NCT04505722-89e40f6c",
        "title": "Double-blind Phase: Ad26.COV2.S 5*10^10 vp vs Double-blind Phase: Placebo: Number of Participants With Medically-Attended Adverse Events (MAAEs) (Double Blind Phase)",
        "summary": "1672 of 21894 against 1885 of 21882; risk difference -1.0 points, 95% interval -1.5 to -0.5; NCT04505722, A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants",
        "record": "/library/comparisons/NCT04505722-89e40f6c",
        "nct_id": "NCT04505722",
        "kind": "outcome",
        "participants": 43776,
        "risk_difference": {
          "value": -0.009775907844634377,
          "lower": -0.014897463089226789,
          "upper": -0.004657710983545815
        },
        "group_1": "1,672 of 21,894",
        "group_2": "1,885 of 21,882",
        "difference": "-1.0 points",
        "interval": "-1.5 to -0.5",
        "trial_title": "A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=12",
  "request_id": "gs_7Bb4qybZlRxRH"
}